Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The future of cell therapy

G C Yee1

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Florida Health Science Center, Gainesville 32610, USA.

Pharmacotherapy
|May 1, 1996
PubMed
Summary

Peripheral blood stem cell (PBSC) transplants offer rapid recovery but high relapse rates. Novel technologies like positive selection and ex vivo expansion aim to improve outcomes and reduce collection challenges.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

Clinical pharmacology and therapeutics·2006
Same author

Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells.

Bone marrow transplantation·2001
Same author

Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong.

Alimentary pharmacology & therapeutics·2001
Same author

Pharmacoeconomics of biotechnology drugs (2).

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·1998
Same author

The clinical and economic rationale for peripheral blood progenitor cell transplantation. Introduction.

Pharmacotherapy·1998
Same author

Peripheral blood progenitor cell transplantation: economic issues.

Pharmacotherapy·1998

Area of Science:

  • Hematology
  • Transplant Immunology
  • Biotechnology

Background:

  • Peripheral blood stem cells (PBSC) are now preferred over bone marrow for autologous rescue post-chemotherapy.
  • PBSC transplants lead to faster hematopoietic reconstitution and reduced transplant-related mortality.
  • High relapse rates and inconvenient, costly PBSC collection remain significant challenges.

Purpose of the Study:

  • To review current advancements in PBSC transplant technologies.
  • To explore novel methods for improving hematopoietic stem cell collection and therapeutic efficacy.
  • To discuss the potential of allogeneic PBSC and umbilical cord blood transplants.

Main Methods:

  • Review of emerging technologies in hematopoietic stem cell collection and manipulation.
  • Discussion of positive selection devices for hematopoietic stem cells.
  • Exploration of ex vivo expansion techniques for hematopoietic progenitor and immune effector cells.
  • Consideration of allogeneic PBSC and umbilical cord blood as alternative stem cell sources.

Main Results:

  • Positive selection devices reduce infusion volume, minimizing adverse effects and potentially purging tumor cells.
  • Ex vivo expansion can generate large numbers of specific hematopoietic cells or immune effector cells for adoptive immunotherapy.
  • Allogeneic PBSC and umbilical cord blood show promise as sources for allogeneic transplantation.

Conclusions:

  • Novel technologies offer potential solutions to improve PBSC transplant efficacy and patient outcomes.
  • Ex vivo manipulation and alternative stem cell sources are key areas for future research and clinical application.
  • Advancements in stem cell collection and expansion are crucial for overcoming current limitations in transplantation.

Related Experiment Videos